Nitoman (Tetrabenazine)

Tetrabenazine, the active ingredient in Nitoman, is a VMAT2 inhibitor presented as an oral tablet for oral use. It treats Huntington's disease chorea, tardive dyskinesia and other hyperkinetic movement disorders in appropriate patients.

GNH USA supplies Nitoman as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nitoman, a VMAT2 inhibitor, is used to manage hyperkinetic movement disorders.

- Huntington's disease chorea: reduces involuntary choreiform movements. - Tardive dyskinesia: alleviates persistent dyskinetic movements caused by long‑term antipsychotic use. - Other hyperkinetic movement disorders: improves motor control in various dopamine‑mediated conditions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: transient light‑headedness, especially when standing. - Depression: mood changes that may require monitoring.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of suicidal ideation or behavior. - Severe depression: marked depressive episodes requiring immediate attention. - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Hepatic injury: signs of liver dysfunction such as jaundice. - Cardiac arrhythmia: irregular heart rhythms that may need cardiac evaluation.

Before initiating therapy, consider the following precautions.

- Monitor mood: watch for signs of depression or suicidal ideation. - Hepatic function: assess liver enzymes, especially in patients with known liver disease. - Renal impairment: adjust dosing in severe renal dysfunction. - Concomitant CNS depressants: use with caution as additive sedation may occur. - Discontinuation: avoid abrupt cessation; taper under medical supervision. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Tetrabenazine may interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (e.g., benzodiazepines): enhanced sedation and respiratory depression. - Antidepressants (especially SSRIs): potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible additive hypotensive effect. - CYP2D6 inhibitors (e.g., quinidine): increased tetrabenazine plasma concentrations.